Veritas Genetics, a world leader in medical genomics, has acquired qGenomics, a leading company in carrier screening and array analysis, founded in 2008 as a spin-off company from the BIST Community centre CRG and Pompeu Fabra University. The scientific and technological expertise of qGenomics will allow Veritas to expand its offering in perinatal and clinical genetics.
Lluís Armengol from qGenomics (left) and Javier de Echaverría, CEO of Veritas Genetics (right)
Founded in 2008 by Lluís Armengol, Xavier Estivill, and Luis Pérez Jurado, as a spin-off of the Centre for Genomic Regulation (CRG) and Pompeu Fabra University (UPF), qGenomics has been a scientific and technological benchmark in genomics for more than fifteen years.
The company has had the support of leading investors in the clinical and diagnostic sector, such as the Dexeus Mujer Group and Laboratorio Echevarne. With the mission of bringing research closer to clinical practice, the company has led national and international initiatives in the diagnosis of rare diseases and chromosomal disorders, serving both the public and private sectors.
The founding partners and investors of qGenomics have reinvested in Paulus Holdings, the investment vehicle of Veritas Genetics.
Javier de Echevarría, CEO of Veritas Genetics, says: “With this acquisition, Veritas integrates qGenomics’ solid capabilities in technologies such as arrays and carrier screening, which strengthens our offering in perinatal and clinical genetics. In addition, it paves the way for the launch of qCarrier at the end of 2025, completing a comprehensive portfolio that supports healthcare professionals and empowers patients at every stage of life. We are proud to welcome the qGenomics team, combining scientific excellence with a shared mission of advancing genomic medicine.”
For his part, Lluís Armengol, co-founder and CEO of qGenomics, added, “Joining Veritas Genetics is a natural evolution for qGenomics. It allows us to amplify our scientific impact, strengthen our diagnostic capabilities, and continue serving patients and healthcare professionals with the same rigor and commitment that has defined us since day one.”
Amengol will remain with the group and has been appointed Chief Scientific Officer of Veritas Genetics.
